Ireland's Theravance Biopharma Q4 revenue misses expectations

Theravance Biopharma

19/03/2026 12:43

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * Ireland-based respiratory medicines developer's Q4 revenue missed analyst expectations
    * Company to cut operating expenses by about 60%

    
    Outlook
  
    * Theravance expects $60-$70 mln annualized cash flow starting in Q3 2026
    * Company projects operating expenses to drop about 60% after restructuring
    * Theravance says Strategic Review Committee is accelerating evaluation of alternatives, including potential sale

    
    Result Drivers
  
    * YUPELRI SALES GROWTH - Q4 YUPELRI net sales rose year-over-year, driven by 14% growth in customer demand and 13% higher hospital channel volumes
    * MILESTONE PAYMENTS - Q4 results benefited from $25 mln YUPELRI and $50 mln TRELEGY sales-based milestone payments

    
Company press release:  ID:nPn26N9d9a 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4        Miss      $45.9     $58.50
 Revenue             mln       mln (6
                               Analysts
                               )
 Q4 EPS              $1.15      
 Q4                  $3.13      
 Adjusted            mln       
 Net                           
 Income                        
 Q4 Net              $61.02     
 Income              mln       
 Q4                  $20.01     
 Operatin            mln       
 g Income                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the pharmaceuticals peer group is "buy"
    * Wall Street's median 12-month price target for Theravance Biopharma Inc is $15.00, about 8.5% above its March 18 closing price of $13.83
    * The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 21 three months ago

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)